Worcester-based Biovest International Inc. was recently cited in the 9/20 edition of the Journal of the National Cancer Institute, lending independent support to its ongoing phase 3 trial of BioVaxID.
BioVaxID, an autologous immunotherapy for follicular non-Hodgkin’s Lymphoma, received mention from an article published in the Journal entitled, “Clinical Benefit Associated With Idiotypic Vaccination of Patients With Follicular Lymphoma” by Susana Inoges.Â
The significance of the findings reveal that researchers using similar methods of developing anti-idiotype vaccines as BioVest Intl. recorded that the immune system response showed a “highly statistical significant increase in disease-free survival.”
Research was conducted at the Oncology Division of the University of Navara in Spain.
Â
